Condition (MeSH)
Polyendocrinopathies, Autoimmune
ClinicalTrials.gov lists 15 trials for Polyendocrinopathies, Autoimmune or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
15 of the 15 trials are tagged with Polyendocrinopathies, Autoimmune itself; the rest are tagged with a narrower condition beneath it.
When did Polyendocrinopathies, Autoimmune trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Polyendocrinopathies, Autoimmune trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 4 |
| Not applicable | 4 |
| Observational | 7 |
How many Polyendocrinopathies, Autoimmune trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Completed | 7 |
| Terminated | 1 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Polyendocrinopathies, Autoimmune trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| Institut National de la Santé Et de la Recherche Médicale, France | 1 |
| Matinas BioPharma Nanotechnologies, Inc. | 1 |
| National Human Genome Research Institute (NHGRI) | 1 |
| National Institutes of Health Clinical Center (CC) | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Polyendocrinopathies, Autoimmune? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Emapalumab | 1 |
| AMPHOTERICIN B | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| OD dual-release Hydrocortisone | 1 |
| Ruxolitinib IR | 1 |
| Synthetic Human Parathyroid Hormone 1-34 pump | 1 |
| Collection of samples | 1 |
| Hydrocortisone 1% | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Polyendocrinopathies, Autoimmune trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 2 | 1 |
| Abdominal pain | 1 | 1 |
| Adrenal insufficiency | 1 | 1 |
| Colostomy closure | 1 | 1 |
| Dysphagia | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Polyendocrinopathies, Autoimmune? (20)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Lessons From Prospective Longitudinal Follow-up of a French APECED Cohort. | The Journal of clinical endocrinology and metabolism | 2025 | Yes |
| Case report: Discovery of a <i>de novo FAM111B</i> pathogenic variant in a patient with an APECED-like clinical phenotype. | Frontiers in immunology | 2023 | Yes |
| APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly American Cohort. | Hepatology (Baltimore, Md.) | 2021 | Yes |
| Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome. | Frontiers in immunology | 2018 | Yes |
| Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. | The Journal of allergy and clinical immunology | 2013 | Yes |
Showing 5 of 20 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Autoimmune polyendocrinopathy | 282196 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Autoimmune polyendocrinopathy | 282196 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.